MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours

Kamali, Firouzeh; Wang, Wei Lien; Guadagnolo, B. Ashleigh; Fox, Patricia S.; Lewis, Valerae O.; Lazar, Alexander J.; Conley, Anthony P.; Ravi, Vinod; Toliyat, Mohammad; Ladha, Harshad; Hobbs, Brian P.; Amini, Behrang

doi:10.1259/bjr.20150308

Cited by 18 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to previous efforts at deriving prognostic factors from clinical variables (17,26,31), other characteristics and MRI features, including size, age, gender, dominant shape, multifocality, adjacent structure involvement, and compartment of origin, were not associated with PFS. Since our study participants were patients treated with imatinib, it might introduce a selection bias, and hence, the findings cannot invalidate the results of the previous study, which included a larger number of patients.…”

Section: Discussioncontrasting

confidence: 91%

MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis

Zhu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo investigate the efficiency of pre-therapy magnetic resonance imaging (MRI) features in predicting the prognosis of desmoid-type fibromatosis patients treated with imatinib.Materials and MethodsA total of 38 desmoid-type fibromatosis patients treated with imatinib were collected in this retrospective study. The high signal intensity on pre-therapy MRI was evaluated on axial T2 and T1 contrast-enhanced sequences with fat suppression. Cox regression and Kaplan–Meier analyses explored the correlation between clinical or radiographic characteristics and progression-free survival (PFS).ResultsHyperintense T1 contrast enhancement (CE) proportion (≥ 75%) was identified as an independent predictor for PFS. Patients with hyperintense T1 CE proportion <75% demonstrated no progression, while patients with hyperintense T1 CE proportion ≥75% demonstrated a progression rate of 78.4%.ConclusionHyperintense T1 CE proportion in the tumor is a potential predictor of disease progression in patients with desmoid-type fibromatosis treated with imatinib. Hyperintense T1 CE proportion <75% indicates progression-free during treatment.

show abstract

Section: Discussioncontrasting

confidence: 91%

MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis

Zhu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…7). MR characteristics of DF depend upon the histological components of the tumor (Fig 3–4, 7–8) [32, 39–41]. Fibrotic and collagenous portions of DF typically demonstrate low signal intensity on T2 weighted sequences and demonstrate mild to moderate enhancement, especially on the delayed phase post contrast enhanced images; in contrast, prominent cellular stroma and myxoid matrix in DF manifests as heterogeneous T2 hyperintense areas and demonstrate moderate to intense enhancement following intravenous contrast administration.…”

Section: Imaging Featuresmentioning

confidence: 99%

Current Update on Desmoid Fibromatosis

Ganeshan¹,

Amini

Nikolaidis

et al. 2019

J Comput Assist Tomogr

Self Cite

View full text Add to dashboard Cite

Objective: The purpose of this article is to review the etiopathogenesis, molecular cytogenetics, histopathology, clinical features and multimodality imaging features of Desmoid Fibromatosis (DF). Recent advances in the management of Desmoid Fibromatosis will also be discussed. Conclusion: Desmoid Fibromatosis is a rare soft tissue neoplasm with a high incidence of local recurrence. Imaging plays an important role in the diagnosis and management of this disease.

show abstract

“…As the lesion matures, the increase in collagen deposition and decreased cellularity result in a decrease in T2 signal [ 38 , 39 ]. However to date it has not been possible to predict behaviour based on MRI signal [ 40 , 41 ].…”

Section: Introductionmentioning

confidence: 99%

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response

et al. 2018

View full text Add to dashboard Cite

BackgroundOne of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports.MethodsA retrospective database was used to identify consecutive patients diagnosed with aggressive fibromatosis (AF) and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at our tertiary referral centre between 2007 and 2014. MRI and symptom changes were recorded.ResultsThirty-two patients (13 male 19 female, median age 41 years) were included. Median duration of treatment with tamoxifen was 316 days. Of 9 patients with progressive disease by RECIST 1.1 (28%): 4 patients experienced worsening symptoms; 3 patients had improved symptoms and 2 had no change in symptoms. Of 22 patients with stable disease (69%): 11 had no change in symptoms; 6 had improved symptoms and 5 patients had worsening symptoms. One patient achieved a partial response with improved symptoms.ConclusionsNo relationship was identified between symptomatic benefit and response by RECIST 1.1 on MRI. Prospective studies in AF should incorporate endpoints focusing on patient symptoms.

show abstract

MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours

Cited by 18 publications

References 31 publications

MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis

MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis

Current Update on Desmoid Fibromatosis

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response

Contact Info

Product

Resources

About